Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $37.00

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $37.00.

Several equities analysts have recently issued reports on KROS shares. Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Scotiabank lowered their price objective on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating for the company in a research note on Monday, May 12th. Truist Financial dropped their target price on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Wedbush reissued a “neutral” rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Finally, Wells Fargo & Company reduced their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th.

Keros Therapeutics Trading Up 0.2%

Shares of Keros Therapeutics stock opened at $14.10 on Friday. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $72.37. The firm has a market capitalization of $572.67 million, a P/E ratio of -2.71 and a beta of 1.32. The business has a fifty day simple moving average of $12.48 and a two-hundred day simple moving average of $22.30.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million during the quarter, compared to analysts’ expectations of $84.62 million. During the same period last year, the company posted ($1.21) EPS. Analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 20.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently added to or reduced their stakes in KROS. Goldman Sachs Group Inc. lifted its holdings in shares of Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after buying an additional 205,022 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Keros Therapeutics by 15.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares during the last quarter. AQR Capital Management LLC bought a new position in Keros Therapeutics in the first quarter valued at about $226,000. ADAR1 Capital Management LLC lifted its holdings in Keros Therapeutics by 6,294.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after acquiring an additional 1,463,215 shares during the period. Finally, PDT Partners LLC purchased a new position in Keros Therapeutics in the first quarter worth about $2,813,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.